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The prognosis of patients with unresectable or advanced metastatic bone and especially soft-tissue sarcoma (STS) remains poor with a disease-free survival at 5 years of less than 10%. [1] [2] [3] [4] [5] [6] Although treatment of advanced STS is generally considered to be palliative, cure may be possible in a small group of patients. 6 Doxorubicin and ifosfamide are the most active single agents with response rates ranging from 15 to 25%. [7] [8] [9] For ifosfamide a dose response has been documented. [10] [11] [12] [13] Another active single agent in the therapy of STS is cisplatin with a 15% response rate using high doses (200 mg/m 2 ). 14, 15 In phase-II studies different combination chemotherapy regimens based on high doses of ifosfamide, doxorubicin or cisplatin demonstrated response rates of up to 60%. 16, 17 However, phase-III trials using these dose-intensive regimens demonstrated inconsistent benefits in terms of response rates and could not show an improvement in overall survival (OS). [2] [3] [4] [5] High-dose chemotherapy (HDCT) with hematopoietic stem cell support (PBSCT) in the treatment of STS is still not established. The few data using HDCT in the treatment of Ewing's sarcoma, osteosarcoma and rhabdomyosarcoma have demonstrated inconsistent benefits. [18] [19] [20] [21] [22] In some phase-I trials using HDCT in the treatment of patients with different histologic subtypes of adult sarcomas such as liposarcoma, leiomyosarcoma, and malignant fibrous histiocytoma long-term survivors have been reported, [23] [24] [25] [26] but long-term survivors have also been reported with conventional chemotherapy with or without resection. 27 Whether HDCT improves the results in adult patients with bone and STS has not yet been established. 28 Blay et al 29 published the first data on HDCT with PBSCT in adult STS: they were able to demonstrate a benefit for the subgroup of patients who were in complete remission before HDCT.
In this report, we present the results of adult patients with advanced bone and STSs treated with HDCT followed by hematopoietic stem cell support (PBSCT).
Patients and methods

Patients
We analyzed the data of 27 patients with bone and STSs who received HDCT and PBSCT between August 1998 and November 2003 at the Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany. All histologic diagnoses were reviewed by the local pathologist or reviewed by a reference pathologist according to the multicenter studies. Histologies included the Ewing sarcoma family (n ¼ 8), osteosarcomas (n ¼ 6), malignant peripheral nerve sheath tumor (MPNST) (n ¼ 4), synovial sarcomas (n ¼ 3), liposarcomas (n ¼ 2), leiomyosarcomas (n ¼ 2), rhabdomyosarcoma (n ¼ 1) and meningosarcoma (n ¼ 1). A total of 15 patients were female, and 12 were male. Patients were aged between 13 and 59 years; median age at time of transplantation was 30.6 years (range: 13-59). Normal creatinine, normal cardiac function and normal bilirubin levels were required. HDCT was performed in 12 patients as first-line therapy; other patients received HDCT because of locally recurrent disease or progressive lung, bone or skin metastases. Two patients were treated with tandem-PBSCT. Median CD34 þ cell count at PBSCT was 4.9 Â 10 6 CD34 þ cells/kg body weight (range: 2.0-16.7). Following conventional chemotherapy and surgery complete remission (CR) (n ¼ 9), partial remission (PR) (n ¼ 10), stable disease (SD) (n ¼ 2) and progressive disease (PD) (n ¼ 6) were reached prior to PBSCT. 
HDCT regimens and PBSCT
Statistical analysis
No patients were lost to follow-up. The median OS and progression-free survival (PFS) were assessed from the date of HDCT and PBSCT. Values are given as median and range. Survival curves were generated according to the Kaplan-Meier method and calculated from the date of HDCT.
Results
The characteristics of the 27 patients are presented in Table 1 . In 12 patients (44%) HDCT was performed as first-line therapy; 15 patients received HDCT because of locally recurrent disease (30%) or progressive lung, bone or skin metastases (26%). Two patients were treated with tandem-PBSCT.
Toxicity
All patients received a peripheral blood stem cell graft and experienced WHO grade 4 leukopenia, neutropenia and thrombocytopenia after HDCT. There was one sudden death due to cardiac arrest of unknown origin on day 7; autopsy was refused by the family. No other WHO grade III-IV morbidities related to HDCT were observed.
Status prior and after HDCT
All patients were restaged immediately before HDCT. Nine (33%) were in CR after induction chemotherapy before HDCT and none had evidence of disease (NED) after PBSCT. During follow-up, only three patients in the CR group relapsed and two of them died of disease (DOD), so that seven patients are still alive (one is alive with disease, AWD) and six of them are NED. In total, 10 patients (37%) had a PR before HDCT, five of them relapsed within 1 year after PBSCT and died, five are still alive and progression-free. Two patients (8%) showed SD before HDCT, one patient died due to a sudden toxic event on day 7 after PBSCT and one is still AWD. Six patients (22%) demonstrated PD before HDCT, four of them DOD within a median time of 8 months (range: 2-18) after PBSCT, two patients are still AWD.
Survival after HDCT and PBSCT
With a median follow-up of 27 months and a minimum follow-up of 2 months, the median OS from the date of HDCT and PBSCT was 16.5 months (range: 0-58). The median PFS was 12.0 months (range: 0-58). Kaplan-Meier curves for OS and PFS of all 27 patients are shown in Figure 1a and b. Four patients died within a median time of 8 months (range: 2-18) after PBSCT due to PD, in another eight patients disease recurred after PBSCT and led to death in seven of them within a median PFS of 7.1 months (range: 3-19) and a median OS of 16.6 months (range: 7-30), 15 patients are still alive. Nine patients (33%) in CR before HDCT were NED after PBSCT with a median PFS of 25.8 months (range: 3-58) and a median OS of 30.2 months (range: 7-58). The CR patients are described in comparison to the other patients in Table 1 . A KaplanMeier curve for OS of CR patients in comparison to non-CR patients is shown in Figure 1c . Patients in PD before HDCT did not benefit from this strategy.
Discussion
Although few sarcomas including rhabdomyosarcomas, extraskeletal PNETs and synovial sarcomas are chemosensitive, most other bone and STS respond poorly to cytotoxic agents with CR rates hardly exceeding 10% in large series. [1] [2] [3] [4] [5] [10] [11] [12] [13] [14] 16, 17 Very few patients with metastatic STS are long-term survivors 6 and these are frequently patients who achieved complete remission after either chemotherapy or chemotherapy and surgery. 6, 27, 30 To improve the prognosis of bone and STS, a reasonable goal could be to increase the CR rate by treating patients with higher doses of chemotherapy and autologous blood stem cell rescue. However, a large number of phase-II trials including Ewing sarcomas, osteosarcomas and STS showed inconsistent results concerning outcome and benefit for the patients treated with HDCT þ PBSCT. [18] [19] [20] [21] [22] [23] [24] [25] [26] The objective of the present study was to investigate response following conventional chemotherapy with or without surgery. PFS and OS after HDCT and hematopoietic stem cell transplantation were evaluated. Moreover, an evaluation was made concerning whether patients in CR before HDCT demonstrate a better clinical outcome compared to other patients.
The most established conditioning regimen (ICE/PEI) used in this study included ifosfamide, carboplatin and etoposide. The administration of high doses of doxorubicin is limited by extrahematologic toxicity, particularly mucositis and cardiac toxicity. The dose of ifosfamide can be increased up to 18 g/m 2 per course with a significant incidence of neurologic and renal toxicity at doses higher than 14 g/m 2 per course. 11 Cisplatin was also included because it can have antitumor activity in sarcomas at doses of 200 mg/m 2 per course or in addition to ifosfamide. 15 The role of etoposide in the treatment of sarcoma is controversial, 31 but in vitro studies demonstrated a synergistic cytotoxic effect with cisplatin. 32 In our study, toxicity was comparable to the data of Blay et al.
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During follow-up, only three patients of the nine CR patients relapsed and two of them DOD, so that seven patients are still alive (one is AWD) and six of them are NED ( Table 1 ). The present series could possibly indicate that a substantial proportion of patients in CR before HDCT experience long-term survival after HDCT and suggests a possible improvement in survival for this small subgroup of patients. In the published literature (data of the EORTC Soft Tissue and Bone Sarcoma Group and of the EBMT solid tumor working party), the percentage of long-term survivors among STS patients achieving CR after conventional chemotherapy is about 18% in different series. 6, 30, 33 With a median follow-up of 27 months, the median OS from the date of HDCT and PBSCT was 16.5 months (range: 0-58) with a median PFS of 12.0 months (range: 0-58). These data are in line with those of Blay et al. 29 They demonstrated a median OS from the date of HDCT of 19 months and a PFS of 7 months; survival from the initiation of conventional chemotherapy before HDCT was longer, of course, 26 and 14 months, respectively. 29 Fagioli et al 21 showed a median survival time of 20 months in a cohort of 32 patients with metastatic osteosarcoma. Therefore, the results suggest that HDCT may decrease relapse rate and improve survival of patients with bone and STS in CR after conventional chemotherapy. Whether this could also apply to patients in whom CR has been achieved by (Figure 1c ). These observations suggest that HDCT may not benefit patients in less than CR before HDCT. It cannot be excluded, however, that patients converted from PR to CR after HDCT may also benefit from HDCT.
Taken together, these results suggest that HDCT may improve the CR rate of patients with bone and STS. HDCT may also improve the survival of patients in CR before HDCT, although this remains to be established through a randomized trial. In this and other series, long-term survival after HDCT was rarely observed in patients in less than CR before HDCT. This strategy remains, therefore, palliative in most cases and still cannot be considered as standard, compared with less intensive and less toxic conventional treatments. In conclusion, only patients in CR or PR prior HDCT, or those who are likely to achieve CR undergoing surgery if HDCT alone does not result in CR, should be considered for this treatment strategy. We are planning a study treating STS patients with HDCT and PBSCT with the intention to establishing various prognostic factors. For example, we are using PET imaging to evaluate response to induction chemotherapy and to predict whether patients will achieve CR before HDCT. 
